These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 16845632)

  • 1. Tumor-necrosis-factor blockers: differential effects on mycobacterial immunity.
    Saliu OY; Sofer C; Stein DS; Schwander SK; Wallis RS
    J Infect Dis; 2006 Aug; 194(4):486-92. PubMed ID: 16845632
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reactivation of latent tuberculosis by TNF blockade: the role of interferon gamma.
    Wallis RS
    J Investig Dermatol Symp Proc; 2007 May; 12(1):16-21. PubMed ID: 17502864
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of anti-tuberculosis T-lymphocyte function with tumour necrosis factor antagonists.
    Hamdi H; Mariette X; Godot V; Weldingh K; Hamid AM; Prejean MV; Baron G; Lemann M; Puechal X; Breban M; Berenbaum F; Delchier JC; Flipo RM; Dautzenberg B; Salmon D; Humbert M; Emilie D;
    Arthritis Res Ther; 2006; 8(4):R114. PubMed ID: 16859506
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor necrosis factor blockers influence macrophage responses to Mycobacterium tuberculosis.
    Harris J; Hope JC; Keane J
    J Infect Dis; 2008 Dec; 198(12):1842-50. PubMed ID: 18954258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adalimumab induces apoptosis of human monocytes: a comparative study with infliximab and etanercept.
    Shen C; Assche GV; Colpaert S; Maerten P; Geboes K; Rutgeerts P; Ceuppens JL
    Aliment Pharmacol Ther; 2005 Feb; 21(3):251-8. PubMed ID: 15691299
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: comparison among infliximab, etanercept, and adalimumab.
    Mitoma H; Horiuchi T; Tsukamoto H; Tamimoto Y; Kimoto Y; Uchino A; To K; Harashima S; Hatta N; Harada M
    Arthritis Rheum; 2008 May; 58(5):1248-57. PubMed ID: 18438840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor.
    Kaymakcalan Z; Sakorafas P; Bose S; Scesney S; Xiong L; Hanzatian DK; Salfeld J; Sasso EH
    Clin Immunol; 2009 May; 131(2):308-16. PubMed ID: 19188093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reactivation of latent granulomatous infections by infliximab.
    Wallis RS; Broder M; Wong J; Lee A; Hoq L
    Clin Infect Dis; 2005 Aug; 41 Suppl 3():S194-8. PubMed ID: 15983899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential regulation of IFN-gamma, TNF-alpha, and IL-10 production by CD4(+) alphabetaTCR+ T cells and vdelta2(+) gammadelta T cells in response to monocytes infected with Mycobacterium tuberculosis-H37Ra.
    Tsukaguchi K; de Lange B; Boom WH
    Cell Immunol; 1999 May; 194(1):12-20. PubMed ID: 10357876
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mycobacterium tuberculosis-induced cell death of primary human monocytes and macrophages is not significantly modulated by tumor necrosis factor-targeted biologicals.
    Reiling N; Schneider D; Ehlers S
    J Investig Dermatol Symp Proc; 2007 May; 12(1):26-33. PubMed ID: 17502866
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differences between anti-tumor necrosis factor-alpha monoclonal antibodies and soluble TNF receptors in host defense impairment.
    Dinarello CA
    J Rheumatol Suppl; 2005 Mar; 74():40-7. PubMed ID: 15742464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population.
    Ollendorf DA; Klingman D; Hazard E; Ray S
    Clin Ther; 2009 Apr; 31(4):825-35. PubMed ID: 19446156
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytokine production from stimulated whole blood cultures in rheumatoid arthritis patients treated with various TNF blocking agents.
    Popa C; Barrera P; Joosten LA; van Riel PL; Kullberg BJ; van der Meer JW; Netea MG
    Eur Cytokine Netw; 2009 Jun; 20(2):88-93. PubMed ID: 19541595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The infectious profiles of anti-tumor necrosis factor agents in a Thai population: a retrospective study a the university-based hospital.
    Suwannalai P; Auethavekiat P; Udomsubpayakul U; Janvitayanujit S
    Int J Rheum Dis; 2009 Jul; 12(2):118-24. PubMed ID: 20374328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumour necrosis factor-alpha chimeric antibody (infliximab) inhibits activation of skin-homing CD4+ and CD8+ T lymphocytes and impairs dendritic cell function.
    Bedini C; Nasorri F; Girolomoni G; Pità Od; Cavani A
    Br J Dermatol; 2007 Aug; 157(2):249-58. PubMed ID: 17489975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor necrosis factor inhibitors block apoptosis of human epithelial cells of the salivary glands.
    Sisto M; D'Amore M; Caprio S; Mitolo V; Scagliusi P; Lisi S
    Ann N Y Acad Sci; 2009 Aug; 1171():407-14. PubMed ID: 19723083
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor necrosis factor and its blockade in granulomatous infections: differential modes of action of infliximab and etanercept?
    Ehlers S
    Clin Infect Dis; 2005 Aug; 41 Suppl 3():S199-203. PubMed ID: 15983900
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential effects of anti-TNF-alpha drugs on fibroblast-like synoviocyte apoptosis.
    Pattacini L; Boiardi L; Casali B; Salvarani C
    Rheumatology (Oxford); 2010 Mar; 49(3):480-9. PubMed ID: 20040530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How tumour necrosis factor blockers interfere with tuberculosis immunity.
    Harris J; Keane J
    Clin Exp Immunol; 2010 Jul; 161(1):1-9. PubMed ID: 20491796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug insight: different mechanisms of action of tumor necrosis factor antagonists-passive-aggressive behavior?
    Rigby WF
    Nat Clin Pract Rheumatol; 2007 Apr; 3(4):227-33. PubMed ID: 17396108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.